Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo prefecture of Japan in August, 2021

Zhenxiao Ren, Koichi Furukawa, Mitsuhiro Nishimura, Yukiya Kurahashi, Silvia Sutandhio, Lidya Handayani Tjan, Kaito Aoki, Natsumi Hasegawa, Jun Arii, Kenichi Uto, Keiji Matsui, Itsuko Sato, Jun Saegusa, Nonoka Godai, Kohei Takeshita, Masaki Yamamoto, Tatsuya Nagashima, Yasuko Mori
doi: https://doi.org/10.1101/2021.09.26.21264129
Zhenxiao Ren
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koichi Furukawa
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mitsuhiro Nishimura
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yukiya Kurahashi
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Silvia Sutandhio
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lidya Handayani Tjan
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaito Aoki
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natsumi Hasegawa
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Arii
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
DVM, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenichi Uto
2Department of Clinical Laboratory, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keiji Matsui
2Department of Clinical Laboratory, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Itsuko Sato
2Department of Clinical Laboratory, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Saegusa
2Department of Clinical Laboratory, Kobe University Hospital, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nonoka Godai
3Laboratory of Macromolecular Dynamics and X-ray Crystallography, Department of Life Science, University of Hyogo, 3-2-1 Kouto, Kamigori-cho, Ako-gun, Hyogo 678-1297, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kohei Takeshita
4Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center, 1-1-1 Koto, Sayo-cho, Sayo-gun, Hyogo 679-5148 Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaki Yamamoto
3Laboratory of Macromolecular Dynamics and X-ray Crystallography, Department of Life Science, University of Hyogo, 3-2-1 Kouto, Kamigori-cho, Ako-gun, Hyogo 678-1297, Japan
4Life Science Research Infrastructure Group, Advanced Photon Technology Division, RIKEN SPring-8 Center, 1-1-1 Koto, Sayo-cho, Sayo-gun, Hyogo 679-5148 Japan
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuya Nagashima
5Hyogo Prefecture Health Promotion Association, 2-1-12 Arata-cho, Hyogo-ku, Kobe, Hyogo 652-0032, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yasuko Mori
1Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Hyogo 650-0017, Japan
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ymori{at}med.kobe-u.ac.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The situation of the COVID-19 pandemic in Japan is drastically changing in the 2nd year, 2021, due to the appearance of SARS-CoV-2 variants of concern and the roll-out of mass vaccination. In addition to PCR diagnosis, periodic seroepidemiologic surveillance is important to analyze the epidemic situation. In this study, we analyzed the rate of seropositivity for the SARS-CoV-2 N and S antigens in Hyogo prefecture, Japan in August 2021. Sera collected from people who received a health check-up in a clinic of the Hyogo Prefecture Health Promotion Association were subjected to analysis of reactivity to the SARS-CoV-2 N and S antigens by electrochemiluminescence immunoassay (ECLIA) and enzyme-linked immunosorbent assay (ELISA), respectively. For a total 1,000 sera, the positive rates to N and S antigens were 2.1% and 38.7%, respectively. The infectious rate estimated by serological analysis based on the presence of the anti-N antibody was 2.5-fold higher than the value reported based on PCR-based analysis, and it increased five-fold compared to the rate determined by our previous seroepidemiologic study in October, 2020. The anti-S positive rate was almost consistent with the vaccination rate in this area. The observed high anti-S antibody level in the seropositive population may indicate that the mass vaccination in Japan is being performed smoothly at this time point, although the infectious rate has also increased.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

No clinical trial in this manuscript.

Funding Statement

This work was supported by Hyogo Prefectural Government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the ethical committees of Kobe University Graduate School of Medicine (approval codes: B2156702). Hyogo Prefecture Health Promotion Association was also granted approval under the ethical committee of Kobe University Graduate School of Medicine. Information about this retrospective observational study was published on the website of Kobe University Hospital, along with the opportunity to opt out. To validate the ELISA, sera from COVID-19 patients and healthy volunteers were used under approval of the ethical committee of Kobe University Graduate School of Medicine (approval code B200200), and written informed consent was obtained from the donors.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

There is no available data referred to the manuscript.

  • Abbreviations

    COVID-19
    Coronavirus disease 2019
    SARS-CoV-2
    Severe acute respiratory syndrome coronavirus 2
    ECLIA
    Electrochemiluminescence immunoassay
    ELISA
    Enzyme-linked inmmunosorbent assay
    N
    Nucleocapsid
    S
    Spike
    PBS
    phosphate buffered saline
    COI
    cut-off index
    ABTS
    2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted September 28, 2021.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo prefecture of Japan in August, 2021
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo prefecture of Japan in August, 2021
    Zhenxiao Ren, Koichi Furukawa, Mitsuhiro Nishimura, Yukiya Kurahashi, Silvia Sutandhio, Lidya Handayani Tjan, Kaito Aoki, Natsumi Hasegawa, Jun Arii, Kenichi Uto, Keiji Matsui, Itsuko Sato, Jun Saegusa, Nonoka Godai, Kohei Takeshita, Masaki Yamamoto, Tatsuya Nagashima, Yasuko Mori
    medRxiv 2021.09.26.21264129; doi: https://doi.org/10.1101/2021.09.26.21264129
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Large-scale seroepidemiologic surveillance of COVID-19 - Cross-sectional study in Hyogo prefecture of Japan in August, 2021
    Zhenxiao Ren, Koichi Furukawa, Mitsuhiro Nishimura, Yukiya Kurahashi, Silvia Sutandhio, Lidya Handayani Tjan, Kaito Aoki, Natsumi Hasegawa, Jun Arii, Kenichi Uto, Keiji Matsui, Itsuko Sato, Jun Saegusa, Nonoka Godai, Kohei Takeshita, Masaki Yamamoto, Tatsuya Nagashima, Yasuko Mori
    medRxiv 2021.09.26.21264129; doi: https://doi.org/10.1101/2021.09.26.21264129

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (349)
    • Allergy and Immunology (668)
    • Allergy and Immunology (668)
    • Anesthesia (181)
    • Cardiovascular Medicine (2648)
    • Dentistry and Oral Medicine (316)
    • Dermatology (223)
    • Emergency Medicine (399)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
    • Epidemiology (12228)
    • Forensic Medicine (10)
    • Gastroenterology (759)
    • Genetic and Genomic Medicine (4103)
    • Geriatric Medicine (387)
    • Health Economics (680)
    • Health Informatics (2657)
    • Health Policy (1005)
    • Health Systems and Quality Improvement (985)
    • Hematology (363)
    • HIV/AIDS (851)
    • Infectious Diseases (except HIV/AIDS) (13695)
    • Intensive Care and Critical Care Medicine (797)
    • Medical Education (399)
    • Medical Ethics (109)
    • Nephrology (436)
    • Neurology (3882)
    • Nursing (209)
    • Nutrition (577)
    • Obstetrics and Gynecology (739)
    • Occupational and Environmental Health (695)
    • Oncology (2030)
    • Ophthalmology (585)
    • Orthopedics (240)
    • Otolaryngology (306)
    • Pain Medicine (250)
    • Palliative Medicine (75)
    • Pathology (473)
    • Pediatrics (1115)
    • Pharmacology and Therapeutics (466)
    • Primary Care Research (452)
    • Psychiatry and Clinical Psychology (3432)
    • Public and Global Health (6527)
    • Radiology and Imaging (1403)
    • Rehabilitation Medicine and Physical Therapy (814)
    • Respiratory Medicine (871)
    • Rheumatology (409)
    • Sexual and Reproductive Health (410)
    • Sports Medicine (342)
    • Surgery (448)
    • Toxicology (53)
    • Transplantation (185)
    • Urology (165)